

CASE STUDY

Sponsor's Groundbreaking Pneumococcal Vaccine Portfolio Receives FDA Priority Review with Support from WCG

CHALLENGE

A top 5 sponsor faced the challenge of enrolling participants on a groundbreaking, global pneumococcal vaccine trial for older adults.

WCG TOTAL FUNNEL METRICS

- 850+ Pre-Screened
- 800+ Referrals
- 300+ Appointments Scheduled
- 250+ First Office Visits
- 250+ Consented
- 250+ Enrollments

SITE SPOTLIGHT

Site A (Austria): WCG enrolled 52 trial participants, 100% of the site's enrollments over the duration of support through a multi-source recruitment strategy tailored to the needs of the site. WCG entered 1,400+ pages and resolved 350+ queries, allowing the site to meet critical data lock timelines.

RESULTS

WCG successfully supported six of eight Phase III studies that contributed to the FDA's priority review of the sponsor's new vaccine.

39%

of total enrollments contributed by WCG at the 13 sites supported.

SOLUTION

Through partnership with WCG, the sponsor received comprehensive support throughout the study, from start-up to close out. This approach enabled close collaboration with each site from the start, identifying and addressing specific support requirements. Our dedicated support throughout the entire process played a crucial role enabling the sponsor to achieve key study objectives and secure priority review from the FDA.